SciELO - Scientific Electronic Library Online

vol.81 issue6Emergency pulmonary lobectomy in a patient with severe hemoptisis due to COVID-19Takotsubo syndrome and multivessel coronary disease author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Medicina (Buenos Aires)

Print version ISSN 0025-7680On-line version ISSN 1669-9106


SANTARELLI, Ignacio M. et al. Subendocardial injury with no evidence of atherosclerosis associated with obinutuzumab infusión. Medicina (B. Aires) [online]. 2021, vol.81, n.6, pp.1052-1055. ISSN 0025-7680.

Obinutuzumab is a fully humanized monoclonal antibody against CD20 used in the treat ment of chronic lymphocytic leukemia. Fatal cardiovascular events have been described, but only in patients with known cardiovascular records. We report the case of an adult male with a high-risk chronic lymphocytic leukemia who developed subendocardial injury, with no evidence of coronary atherosclerosis, during the first administration of obinutuzumab.

Keywords : Obinutuzumab; Subendocardial injury; Adverse reaction; Chronic lymphocytic leukemia.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )